Drug intelligence / Profile preview

MITI-001 (Stanford University)

Development stage: Unknown
Lead developer: Stanford University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MITI-001 is a complex live biotherapeutic product (LBP) consisting of a defined consortium of 157 live bacterial strains representing 79 genera of commensal bacteria. These strains were originally isolated from healthy donor stool, purified, and banked to create a standardized, transplantable gut bacterial community. Developed by researchers at Stanford University and sponsored in clinical trials by EpiCypher, MITI-001 is designed to treat diarrhea-predominant irritable bowel syndrome (IBS-D) by restoring a healthy gut microbiome and correcting microbial metabolic dysfunctions that contribute to IBS symptoms. Unlike traditional fecal microbiota transplantation (FMT), MITI-001 is a defined, manufactured consortium intended to provide a safer and more consistent therapeutic profile by targeting the pathophysiologic lesion in a subset of IBS-D patients.

Targets

GM (Gut microbiome composition and function)Microbial bile acid metabolic pathways

Beyond the preview

Go deeper on MITI-001 (Stanford University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MITI-001 (Stanford University).

Explore the full profile